$30,818.47 speaking Payment -- Pfizer Inc to Dr. Scott Collins

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Pfizer Inc made a $30.8K speaking payment to Scott Collins, a Cardiology specialist in San Jose, CA. The payment was associated with Trulicity. Dr. Scott Collins received $30,818.47 from Pfizer Inc. for speaking engagements related to Trulicity. The payment was for serving as faculty or a speaker, indicating an educational or promotional role. This payment occurred on May 6, 2024, and was processed through the CMS Open Payments system.

Patient Guidance: What This Payment Means for You

If you are a patient prescribed Trulicity, understand that your doctor may receive compensation for educating others about medications. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments to cardiologists for speaking engagements can vary widely, but this amount is on the higher end for a single engagement.

Regulatory Context: Sunshine Act Requirements

Payments to physicians for speaking engagements are reportable under the Sunshine Act, requiring disclosure to ensure transparency in healthcare.

Related Topics

This payment is related to the following healthcare transparency topics:

• speaking-fees
• speaker-program
• pharmaceutical-marketing
• cardiologist-payments
• trulicity
• pfizer-inc

Understanding speaking Payments

Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.

Frequently Asked Questions About This Payment

What was this $30.8K payment for?

This was a speaking payment of $30.8K from Pfizer Inc to Scott Collins, categorized as "Compensation for serving as faculty or as a speaker". It was associated with Trulicity. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Scott Collins accept pharmaceutical money?

Yes, Scott Collins received this $30.8K payment from Pfizer Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Scott Collins's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this speaking payment?

A speaking payment of $30.8K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Cardiology?

To compare this payment against Cardiology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Cardiology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Scott Collins's relationship with Pfizer Inc?

The payment amount is substantial, suggesting significant speaking activity. This $30.8K speaking payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Cardiology?

The specific drug mentioned, Trulicity, is a GLP-1 receptor agonist used for type 2 diabetes.

What should patients do after learning about this payment?

If you are a patient prescribed Trulicity, understand that your doctor may receive compensation for educating others about medications.

What else should I know about this speaking payment?

The payment was made directly to Dr. Collins, not through an intermediary organization.

Related Reports

• View Dr. Scott Collins's full payment report
• Pfizer Inc full spending report
• Browse all Cardiology payments
• Browse all payments in California
• Search for other payments